Sarah E. Taylor

Also affiliated with Edinburgh Cancer Research, Magee-Womens Research Institute, Magee-Womens Hospital, Mayo Clinic Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Phase II clinical trial of metformin as a cancer stem cell–targeting agent in ovarian cancer”.

Phase II clinical trial of metformin as a cancer stem cell–targeting agent in ovarian cancer

JCI Insight(2020)10.1172/jci.insight.133247

N/A

3.2DataRank · unranked

193 citations

Daniel Chan, Jessica Shank, Kent A. Griffith, Huihui Fan, Robert Szulawski +17 more

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.07.008

N/A

0.208DataRank · unranked

3 citations

Ashley Haggerty, Stefan M. Gysler, Sarah E. Taylor, Kian Behbakht, Jill Alldredge +10 more

Same-day Hospital Discharge after Minimally Invasive Hysterectomy in a Gynecologic Oncology Practice: Feasibility, Safety, Predictors of Admission, and Adverse Outcomes

Journal of Minimally Invasive Gynecology(2022)10.1016/j.jmig.2022.05.010

N/A

0DataRank · unranked

18 citations

Michael G. Cohen, C. Toal, Mia Kulinsky, Jennifer Holder‐Murray, Stephen A. Esper +4 more

Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.101080

N/A

0DataRank · unranked

13 citations

Alyssa Wield, Brigid Mumford, Isabel Janmey, Li Wang, Philip J. Grosse +13 more

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

British Journal of Cancer(2022)10.1038/s41416-022-02014-y

N/A

0DataRank · unranked

7 citations

Eunyoung Kang, Nicola S. Meagher, Gregg Nelson, Prafull Ghatage, Cheng‐Han Lee +88 more

Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad011

N/A

0DataRank · unranked

26 citations

Maria M. Brooks, Sarah Irvin, Susan J. Jordan, Katja K.H. Aben, Hoda Anton‐Culver +58 more

The feasibility, acceptability, and preliminary efficacy of a self‐advocacy serious game for women with advanced breast or gynecologic cancer

Cancer(2023)10.1002/cncr.34887

N/A

0DataRank · unranked

12 citations

Catherine M. Bender, Heidi Donovan, Patty Jo Murray, Sarah E. Taylor, Margaret Rosenzweig +4 more

“I was never one of those people who just jumped right in for me”: patient perspectives on self-advocacy training for women with advanced cancer

Supportive Care in Cancer(2023)10.1007/s00520-022-07531-3

N/A

0DataRank · unranked

9 citations

Patty Jo Murray, Margaret Rosenzweig, Sarah E. Taylor, Adam Brufsky, Catherine M. Bender +3 more

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3552

N/A

0DataRank · unranked

14 citations

Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer +93 more

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.05.013

N/A

0DataRank · unranked

2 citations

Lauren Borho, Sarah E. Taylor, Linda E Kelemen, Anna deFazio, Penelope M. Webb +64 more

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA -deficient tubo-ovarian high-grade serous carcinoma

medRxiv(2025)10.1101/2025.09.17.25335919

N/A

0DataRank · unranked

0 citations

Sián Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa Jayawardana, Laura Twomey +95 more

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

Research Square(2025)10.21203/rs.3.rs-7572112/v1

N/A

0DataRank · unranked

0 citations

Tibor A. Zwimpfer, Sián Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa Jayawardana +95 more

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin(2021)10.1007/s00428-021-03232-0

N/A

0DataRank · unranked

23 citations

Joshua Millstein, Gordana Popović, Nicola S. Meagher, Adelyn Bolithon, Aline Talhouk +95 more